| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -640.68% | -62997.35% | -8981.42% | -8684.51% | -7299.12% | -10819.48% | -994.00% | -1895.93% | -3270.27% | -427.39% | -209.25% | -7968.00% |
| EBITDA Margin | -638.49% | -62992.04% | -8974.34% | -8678.32% | -7292.92% | -10813.85% | -993.36% | -1891.45% | -3259.09% | -425.66% | -207.94% | -7913.75% |
| Net Margin | 328.67% | -73682.74% | -8384.07% | -8391.15% | -7151.77% | -10890.48% | -985.02% | -1675.33% | -3061.25% | -354.62% | -209.31% | -7960.25% |
| Current Ratio | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 | 1.97 | 2.83 | 2.11 | 0.49 | 2.27 | 3.05 | 4.57 |
| Quick Ratio | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 | 1.97 | 2.83 | 2.11 | 0.49 | 2.27 | 3.05 | 4.57 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -1457.87% | 526.47% | -177.55% | -66.99% | -35.05% | -407.40% | -185.79% | -381.90% | 221.82% | -383.60% | -221.21% | -269.59% |
| ROA | 86.37% | -667.11% | -83.53% | -48.17% | -29.13% | -125.87% | -90.83% | -114.79% | -483.87% | -84.65% | -102.28% | -134.53% |
| Asset Turnover | 0.26 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.09 | 0.07 | 0.16 | 0.24 | 0.49 | 0.02 |
| Book Value / Share | -0.08 | -20.37 | 0.51 | 1.35 | 2.74 | 0.53 | 0.80 | 1.31 | -1.21 | 1.16 | 0.48 | 1.09 |
Traws Pharma Inc. is a distinguished name in the pharmaceutical industry, primarily focused on the research, development, and commercialization of innovative treatments for a diverse range of medical conditions. With a strong commitment to advancing medical science, Traws Pharma operates at the intersection of cutting-edge biotechnology and classic pharmaceutical expertise. Its product pipeline includes groundbreaking therapies targeting oncology, rare genetic disorders, and metabolic diseases, showcasing its adaptability and dedication to addressing complex health challenges. The company plays a significant role in the healthcare sector, contributing to enhanced patient outcomes and pioneering medical advancements. Traws Pharma's collaborations with leading research institutions and its sustainable growth strategies reinforce its place in the market as a forward-thinking entity. As an active player in the global pharmaceutical landscape, it leverages its robust R&D infrastructure and regulatory expertise to bring new treatments to market efficiently. Founded with the mission to improve lives through science, Traws Pharma Inc. is well-regarded for its patient-centric approach and its unwavering focus on quality and efficacy. Its leadership in therapeutic innovation continues to drive significant impact across multiple healthcare domains.